Showing results (101-110 of 108) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 108 results.
Drug and Alcohol Dependence|June 22, 2026
Hippocampal volume alterations in opioid use disorder: Evidence for posterior vulnerability and heterogeneityPaul S Regier, Delaney McKinstry, Joel M Stein, et al.
Vascular Pharmacology|May 14, 2005
The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effectAdaani E Frost, D Langleben, R Oudiz, et al.
Addiction Biology|September 27, 2023
Hippocampal volume loss in individuals with a history of non-fatal opioid overdoseDustin R Todaro, Xinyi Li, Laís S Pereira-Rufino, et al.
Addiction Biology|September 23, 2016
Emotional, physical and sexual abuse are associated with a heightened limbic response to cocaine cuesPaul S Regier, Zachary A Monge, Teresa R Franklin, et al.
Circulation|June 29, 1999
Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertensionD Langleben, R J Barst, D Badesch, et al.
The New England Journal of Medicine|February 1, 1996
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertensionR J Barst, L J Rubin, W A Long, et al.
Circulation|March 18, 1997
Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study GroupA L Hinderliter, P W Willis, R J Barst, et al.
Annals of Internal Medicine|March 25, 2000
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trialD B Badesch, V F Tapson, M D McGoon, et al.
Pageof 11